This article is more than 5 years old. Information may no longer be current.

Etanercept no better, worse than placebo in preventing uveitis relapse

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — Etanercept has not been shown to have any significant efficacy over placebo in preventing relapses of uveitis patients being tapered from methotrexate, according to a study.

C. Stephen Foster, MD, and colleagues with the Massachusetts Eye and Ear Infirmary randomized 20 patients with chronic or recurrent noninfectious uveitis currently controlled by low-dose methotrexate to receive either etanercept or placebo. Patients were tapered off of the methotrexate and followed for 24 weeks on the new regimen. Thirty percent of the treatment group and 50% of the control group relapsed.

The study is published in the April issue of Archives of Ophthalmology.